Edwards Lifesciences Co. (NYSE:EW - Free Report) - Stock analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Edwards Lifesciences in a research note issued on Wednesday, December 4th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will earn $0.60 per share for the quarter, down from their previous forecast of $0.62. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $2.43 EPS and FY2026 earnings at $2.84 EPS.
Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts' consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business's quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the company earned $0.59 EPS.
EW has been the topic of a number of other research reports. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the company a "hold" rating in a research note on Thursday. Daiwa America downgraded Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 30th. UBS Group dropped their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research note on Tuesday, September 10th. Oppenheimer reaffirmed an "outperform" rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Finally, Jefferies Financial Group downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus target price of $78.35.
Check Out Our Latest Research Report on Edwards Lifesciences
Edwards Lifesciences Trading Down 0.9 %
Shares of EW stock traded down $0.67 during trading hours on Monday, reaching $70.86. The company had a trading volume of 2,134,240 shares, compared to its average volume of 4,637,295. The company has a 50 day moving average of $68.65 and a 200 day moving average of $74.41. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $41.79 billion, a price-to-earnings ratio of 10.32, a P/E/G ratio of 3.52 and a beta of 1.12. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12.
Hedge Funds Weigh In On Edwards Lifesciences
A number of institutional investors have recently modified their holdings of the business. Wellington Management Group LLP grew its holdings in shares of Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. State Street Corp grew its holdings in shares of Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock worth $1,733,270,000 after purchasing an additional 256,538 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company's stock worth $1,827,347,000 after purchasing an additional 809,605 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 2.2% during the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock worth $889,050,000 after purchasing an additional 284,918 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company's stock worth $599,078,000 after purchasing an additional 806,705 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.
Insider Buying and Selling at Edwards Lifesciences
In related news, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock worth $2,657,000 over the last ninety days. Insiders own 1.27% of the company's stock.
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Read More
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.